Navigation Links
Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
Date:9/30/2009

sychiatry).

Douglas Winship, Catalyst's Vice President of Regulatory Operations, commented, "The CPP-01004 clinical trial was a landmark first-in-class U.S. study and to our knowledge, the first large trial conducted in cocaine-dependent subjects of an orally administered medication in which extensive post-hoc objective measurements of medication levels in subjects to verify compliance were performed. Addicted subjects are an extremely difficult and unreliable population in which to conduct clinical trials. In addition, there are no established FDA guidelines for addiction trials. Based on numerous publications of data from previous addiction trials in which historical compliance rates of greater than 85% as measured by pill count and self-report were reported, we believed that our trial was sufficiently powered with 180 subjects. Unfortunately, due to the significantly lower verified actual compliance we found in our trial, there was insufficient power to detect a statistically significant difference between CPP-109 and placebo on the primary or secondary efficacy outcomes. We will continue to complete additional analysis as part of our goal to present our results at appropriate medical conferences in the coming months."

Methamphetamine Study Results

The methamphetamine proof-of concept study enrolled 57 subjects (29 on vigabatrin and 28 on placebo) and there was a 2.5 times higher rate of abstinence in the last two weeks (11 and 12) of the study in the vigabatrin group versus placebo. While this is an encouraging trend, it was not statistically significant due to the small number of subjects in the study. Catalyst further believes that medication compliance may have been below expectations for this study as well.

CPP-109 (Vigabatrin) Safety Results

Regarding the safety of CPP-109, no clinically significant abnormalities in visual fields and visual acuity were found in any subject in
'/>"/>

SOURCE Catalyst Pharmaceutical Partners
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
2. Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial
3. Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
4. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
5. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
6. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
7. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
8. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
9. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
10. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
11. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Actavis plc (NYSE: ACT ... a complete response letter from the U.S. Food ... Application (NDA) for the fixed-dose combination (FDC) of ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... receipt of a complete response letter, Actavis remains ...
(Date:12/24/2014)... Dec. 24, 2014 Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today that on December 24, 2014 it ... The Company raised approximately $2.3 million in ... use the net proceeds from the offering to ...
(Date:12/24/2014)... and FARMINGTON, Conn. , Dec. ... MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific ... significant unmet medical need and commercial potential, today ... placement of 2,050,000 shares of its common stock ... of its common stock.  Funds under the management ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... WATERTOWN, Mass., Oct. 17 EnVivo ... developing drugs for,neurodegenerative diseases, today announced ... Alzheimer,s, Schizophrenia and Huntington,s,diseases. EnVivo ... orally,active Alpha 7 Nicotinic Acetylcholine Receptor ...
... ... flow, muscle oxygen supply, HOBOKEN, N.J., Oct. 17 A ... Pycnogenol(R),(pic-noj-en-all), an antioxidant plant extract from the bark of the French,maritime ... leads to an increase in blood flow and oxygen supply,to muscles. ...
Cached Medicine Technology:EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimer's, Schizophrenia and Huntington's Diseases 2New Study: Pine Bark Extract Boosts Nitric Oxide (NO) Production 2New Study: Pine Bark Extract Boosts Nitric Oxide (NO) Production 3
(Date:12/26/2014)... WA (PRWEB) December 26, 2014 “Many ... deal with personal injury claim issues and phone calls ... recently released an article featuring their free eBook ... exceptionally helpful eBook on pedestrian and bicycle auto accident ... attorney is fully capable of professionally handling their case ...
(Date:12/25/2014)... The microscopy market is estimated ... reach $5,756.0 million by 2019. Optical microscopy is ... electron microscopes product segment is expected to show ... Rising focus on nanotechnology, technological advancements, and increasing ... market. , Get Full Copy of Report @ ...
(Date:12/25/2014)... York, New York (PRWEB) December 25, 2014 ... the 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) ... LLP reports. According to an Order issued in the ... 20th, the Court will convene an open conference on ... Building and United States Courthouse in West Palm Beach, ...
(Date:12/25/2014)... Recently, BellasDress has launched ... wedding dresses. BellasDress has chosen their best-selling lace wedding ... for the holiday season. , Now, BellasDress.com features ... gowns here at discount prices. The business hopes everyone ... website. , “All our elegant products are ...
(Date:12/25/2014)... By Dennis Thompson ... -- Very sick children with complex chronic illnesses can receive ... a "medical home," with easy access to a team of ... were less likely to become seriously ill and need either ... received treatment at an enhanced medical home clinic at the ...
Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3
... In a study to be presented today at ... Pregnancy Meeting , in Chicago, researchers will unveil findings ... adrenal gland is a better predictor of pre-term birth ... of Maryland and Yale University have followed up on ...
... Ill. (February 4, 2010) In a study to be ... meeting, The Pregnancy Meeting , in Chicago, researchers will unveil ... for depression during pregnancy. "Depression during pregnancy is an ... the mother and the baby as well as the rest ...
... , , TORRANCE, Calif. , Feb. ... insurance brokerage and consulting firm in California , has ... best-in-class services.  An example of that commitment to quality and ... division. , TelaDoc is a national network of board-certified physicians ...
... LOUIS , Feb. 3 Young Innovations, Inc. (Nasdaq: YDNT ... 31, 2009 . , Sales for the fourth quarter of 2009 were ... from the $23.9 million reported in the fourth quarter of 2008. ... quarter of 2008 to $5.5 million in the fourth quarter of ...
... February 3, 2010 Recent immigrants to Ontario have ... term residents, according to preliminary study results from researchers at ... (ICES). "What we learned could translate into long-term health ... neurologist at St. Michael,s Hospital. "We need to do further ...
... on Wii boards, report notes , WEDNESDAY, Feb. 3 (HealthDay ... in 2006, more than just the ligaments and tendons in ... new report details foot injuries that have been incurred while ... games were introduced, patients typically presented with ligament injuries of ...
Cached Medicine News:Health News:Ultrasound measurement of fetal adrenal gland a better predictor of preterm birth 2Health News:Acupuncture found effective against depression during pregnancy 2Health News:Keenan Partners With TelaDoc for 24/7 Phone Access to Physician Network 2Health News:Keenan Partners With TelaDoc for 24/7 Phone Access to Physician Network 3Health News:Young Innovations, Inc. Announces Record EPS for the Year 2Health News:Young Innovations, Inc. Announces Record EPS for the Year 3Health News:Young Innovations, Inc. Announces Record EPS for the Year 4Health News:Young Innovations, Inc. Announces Record EPS for the Year 5Health News:Young Innovations, Inc. Announces Record EPS for the Year 6Health News:Young Innovations, Inc. Announces Record EPS for the Year 7Health News:Risk of stroke lower for recent Ontario immigrants: study 2Health News:Wii Popularity Leads to New Kind of Gaming Injury 2Health News:Wii Popularity Leads to New Kind of Gaming Injury 3
Clinac Platinum Plus accelerators offer all the high performance features of the EX series and come with the latest high-precision dose sculpting technology for advanced tumor control....
... EX accelerators are true ... Varian multileaf collimation and ... which enable you to ... computer-driven IMRT treatments, as ...
The Clinac 2300 C/D family of accelerators are reliable, easy-to-use, flexible and cost-effective systems....
... reliable system. Varian accelerators offers highest ... fastest beam-on times to full stability ... milliseconds, pulse-to-pulse beam control for dynamic ... of multileaf collimator (MLC) products that ...
Medicine Products: